(Q27011747)

Steven D Gore

series ordinal

2

1 reference

Amer M Zeidan

series ordinal

3

1 reference

language of work or name

1 reference

August 2013

1 reference

Expert Review of Hematology

published in

1 reference

volume

6

1 reference

issue

4

1 reference

page(s)

397-410

1 reference

Myelodysplastic syndromes: what do hospitalists need to know?

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4124619

Epidemiology of myelodysplastic syndromes

21 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4124619

International scoring system for evaluating prognosis in myelodysplastic syndromes

21 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4124619

Selective iron deposition in pancreatic islet B cells of transfusional iron-overloaded autopsy cases

21 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4124619

Myelodysplastic syndromes: toward a risk-adapted treatment approach

21 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4124619

Myelodysplastic syndromes: who and when in the course of disease to transplant

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4124619

Revised international prognostic scoring system for myelodysplastic syndromes

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4124619

Pre-transplantation iron chelation in patients with MDS or acute leukemia and iron overload undergoing myeloablative allo-SCT.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4124619

Pathophysiological and clinical aspects of iron chelation therapy in MDS.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4124619

A review of anemia as a cardiovascular risk factor in patients with myelodysplastic syndromes.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4124619

Hematologic responses to deferasirox therapy in transfusion-dependent patients with myelodysplastic syndromes

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4124619

Patient and physician characteristics associated with erythropoiesis-stimulating agent use in patients with myelodysplastic syndromes

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4124619

Deferasirox treatment of iron-overloaded chelation-naïve and prechelated patients with myelodysplastic syndromes in medical practice: results from the observational studies eXtend and eXjange

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4124619

Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS)

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4124619

The relevance of iron overload and the appropriateness of iron chelation therapy for patients with myelodysplastic syndromes: a dialogue and debate

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4124619

A European survey on the detection and management of iron overload in transfusion-dependent patients with MDS.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4124619

The role of iron chelation therapy for patients with myelodysplastic syndromes

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4124619

NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromes

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4124619

Iron-chelating therapy for transfusional iron overload

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4124619

Positive effects on hematopoiesis in patients with myelodysplastic syndrome receiving deferasirox as oral iron chelation therapy: a brief review

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4124619

Controversies surrounding iron chelation therapy for MDS.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4124619

The struggle for iron - a metal at the host-pathogen interface.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4124619

Iron chelation therapy in myelodysplastic syndromes.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4124619

Deferasirox is a powerful NF-kappaB inhibitor in myelodysplastic cells and in leukemia cell lines acting independently from cell iron deprivation by chelation and reactive oxygen species scavenging

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4124619

Incidence and clinical complications of myelodysplastic syndromes among United States Medicare beneficiaries

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4124619

Cause of death in patients with lower-risk myelodysplastic syndrome

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4124619

Clinical management of myelodysplastic syndromes: update of SIE, SIES, GITMO practice guidelines.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4124619

NCCN Task Force: Transfusion and iron overload in patients with myelodysplastic syndromes

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4124619

Supportive care and chelation therapy in MDS: are we saving lives or just lowering iron?

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4124619

Prognostic impact of pre-transplantation transfusion history and secondary iron overload in patients with myelodysplastic syndrome undergoing allogeneic stem cell transplantation: a GITMO study

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4124619

Red blood cell transfusion therapy and iron chelation in patients with myelodysplastic syndromes

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4124619

Treatment of transfusional iron overload in patients with myelodysplastic syndrome or severe anemia: data from multicenter clinical practices

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4124619

Objectives of iron chelation therapy in myelodysplastic syndromes: more than meets the eye?

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4124619

Clinical relevance of anemia and transfusion iron overload in myelodysplastic syndromes

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4124619

Iron acquisition: a novel perspective on mucormycosis pathogenesis and treatment

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4124619

Characteristics of US patients with myelodysplastic syndromes: results of six cross-sectional physician surveys

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4124619

Red blood cell transfusion dependence and outcome after allogeneic peripheral blood stem cell transplantation in patients with de novo myelodysplastic syndrome (MDS)

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4124619

Iron chelation therapy in patients with myelodysplastic syndromes: consensus conference guidelines

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4124619

Overview of guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4124619

Japanese epidemiological survey with consensus statement on Japanese guidelines for treatment of iron overload in bone marrow failure syndromes

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4124619

Iron overload in myelodysplastic syndromes

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4124619

Iron overload in myelodysplastic syndromes (MDS) - diagnosis, management, and response criteria: a proposal of the Austrian MDS platform

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4124619

A prognostic score for patients with acute leukemia or myelodysplastic syndromes undergoing allogeneic stem cell transplantation.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4124619

Improving clinical outcome in patients with myelodysplastic syndrome and iron overload using iron chelation therapy

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4124619

Impact of transfusion dependency and secondary iron overload on the survival of patients with myelodysplastic syndromes

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4124619

Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4124619

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4124619

Oxidative stress and the myelodysplastic syndromes

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4124619

Iron toxicity and chelation therapy

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4124619

Prognostication in myelodysplastic syndromes: beyond the International Prognostic Scoring System (IPSS).

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4124619

Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4124619

Pathophysiology of iron overload.

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4124619

Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making.

31 May 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.814456

Retrospective nationwide survey of Japanese patients with transfusion-dependent MDS and aplastic anemia highlights the negative impact of iron overload on morbidity/mortality.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.814456

Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM (Groupe Francophone des Myélodysplasies).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.814456

Iron chelation therapy in MDS: does it improve survival?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.814456

International MDS risk analysis workshop (IMRAW)/IPSS reanalyzed: impact of cytopenias on clinical outcomes in myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.814456

A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.814456

Labile plasma iron in iron overload: redox activity and susceptibility to chelation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.814456

Changes in parameters of oxidative stress and free iron biomarkers during treatment with deferasirox in iron-overloaded patients with myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.814456

ALK+ histiocytosis: a novel type of systemic histiocytic proliferative disorder of early infancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.814456

Iron overload impairs proliferation of erythroid progenitors cells (BFU-E) from patients with myelodysplastic syndromes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.814456

Myelodysplasia paranoia: iron as the new radon

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.814456

Myocardial iron loading by magnetic resonance imaging T2* in good prognostic myelodysplastic syndrome patients on long-term blood transfusions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.814456

Myocardial iron overload assessment by T2* magnetic resonance imaging in adult transfusion dependent patients with acquired anemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.814456

Neither serum ferritin nor the number of red blood cell transfusions affect overall survival in refractory anemia with ringed sideroblasts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.814456

Iron overload and chelation therapy in patients with low-risk myelodysplastic syndromes with transfusion requirements.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.814456

Risk-adapted treatment of acute promyelocytic leukemia with all-trans retinoic acid and anthracycline monochemotherapy: long-term outcome of the LPA 99 multicenter study by the PETHEMA Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.814456

A pilot MRI study of organ specific hemosiderosis and functional correlation in Chinese patients with myelodysplasia and aplastic anemia with raised ferritin levels.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.814456

Iron overload adversely affects outcome of allogeneic hematopoietic cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.814456

Iron chelation therapy in patients with transfusion-dependent myelodysplastic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.814456

Predicted costs of iron-chelators in myelodysplastic syndromes: a 10-year analysis based on actual prevalence and red cell transfusion rates

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.814456

Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.814456

Deferasirox treatment for myelodysplastic syndromes: "real-life" efficacy and safety in a single-institution patient population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.814456

Deferasirox in MDS patients with transfusion-caused iron overload--a phase-II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.814456

Effect of iron overload and iron-chelating therapy on allogeneic hematopoietic SCT in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.814456

Prospective assessment of effects on iron-overload parameters of deferasirox therapy in patients with myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.814456

Improvement of iron-mediated oxidative DNA damage in patients with transfusion-dependent myelodysplastic syndrome by treatment with deferasirox.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.814456

Deferasirox exposure induces reactive oxygen species and reduces growth and viability of myelodysplastic hematopoietic progenitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.814456

Iron status and treatment modalities in transfusion-dependent patients with myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.814456

The costs of drugs used to treat myelodysplastic syndromes following National Comprehensive Cancer Network Guidelines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.814456

Improved survival with iron chelation therapy for red blood cell transfusion dependent lower IPSS risk MDS may be more significant in patients with a non-RARS diagnosis.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4124619

Deferasirox reduces serum ferritin and labile plasma iron in RBC transfusion-dependent patients with myelodysplastic syndrome

28 November 2018

1 reference

12 December 2020

Risk factors for fungal pulmonary infections in hematopoietic stem cell transplantation recipients: the role of iron overload

1 reference

12 December 2020

Retrospective study of the association between transfusion frequency and potential complications of iron overload in patients with myelodysplastic syndrome and other acquired hematopoietic disorders

1 reference

12 December 2020

Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes

1 reference

12 December 2020

High incidence of hemochromatosis gene mutations in the myelodysplastic syndrome: the Budapest Study on 50 patients

1 reference

12 December 2020

Impact of pre-transplant serum ferritin on outcomes of patients with myelodysplastic syndromes or secondary acute myeloid leukaemia receiving reduced intensity conditioning allogeneic haematopoietic stem cell transplantation

1 reference

12 December 2020

Iron overload in myelodysplastic syndromes: a Canadian consensus guideline

1 reference

12 December 2020

Improved survival in MDS patients receiving iron chelation therapy - a matched pair analysis of 188 patients from the Düsseldorf MDS registry

1 reference

12 December 2020

Selective toxicity towards myelodysplastic hematopoietic progenitors - another rationale for iron chelation in MDS

1 reference

12 December 2020

Epidemiology, natural history, and practice patterns of patients with myelodysplastic syndromes in 2010

1 reference

12 December 2020

Efficacy and safety of administration of oral iron chelator deferiprone in patients with early myelodysplastic syndrome

1 reference

12 December 2020

No evidence for myocardial iron overload in multitransfused patients with myelodysplastic syndrome using cardiac magnetic resonance T2 technique

1 reference

12 December 2020

Elevated pretransplant ferritin is associated with a lower incidence of chronic graft-versus-host disease and inferior survival after myeloablative allogeneic haematopoietic stem cell transplantation

1 reference

12 December 2020

Consensus statement on iron overload in myelodysplastic syndromes

1 reference

12 December 2020

10.1586/17474086.2013.814456

Identifiers

DOI

1 reference

1 reference

PubMed publication ID

23991926

1 reference